The LIBRETTO-001 phase I/II study currently aims to assess the clinical safety and efficacy of selpercatinib in patients with advanced RET fusion-positive solid tumors, including NSCLC [130]. This evidence concerns the gene RET and non-small cell lung carcinoma.